Idera announces issuance of U.S. patent covering IMO-8400

theflyonthewall.com

Idera Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400. IMO-8400, an antagonist of Toll-like receptors 7, 8, and 9, is Idera’s lead candidate in development for the treatment of autoimmune diseases. IMO-8400 is currently being evaluated in a Phase 2 trial in patients with moderate-to-severe plaque psoriasis.

Rates

View Comments (1)